Associated Banc Corp Buys 550,546 Shares of Boston Scientific Corporation $BSX

Boston Scientific logo with Healthcare background
Image from MarketBeat Media, LLC.

Key Points

  • Associated Banc Corp initiated a Boston Scientific position, buying 550,546 shares worth about $24.0 million in the third quarter. Institutional investors collectively own 89.07% of the company’s stock.
  • Analyst views were mixed, but the consensus rating was Moderate Buy, with an average price target of $61.43. Recent target changes ranged from a cut to $45 by Barclays to an increase to $51 by Robert W. Baird.
  • Boston Scientific matched quarterly EPS estimates at $0.73 and topped revenue estimates with $5.14 billion; revenue was up 1.4% year over year. Shares opened at $43.58, well below their 12-month high of $105.65.
  • Five stocks we like better than Boston Scientific.

Associated Banc Corp purchased a new stake in shares of Boston Scientific Corporation (NYSE:BSX - Free Report) during the third quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm purchased 550,546 shares of the medical equipment provider's stock, valued at approximately $24,031,000.

Several other large investors have also made changes to their positions in the business. Perigon Wealth Management LLC purchased a new stake in Boston Scientific in the 2nd quarter worth $883,000. Y Intercept Hong Kong Ltd grew its position in shares of Boston Scientific by 148.8% during the second quarter. Y Intercept Hong Kong Ltd now owns 1,120,331 shares of the medical equipment provider's stock valued at $47,816,000 after purchasing an additional 670,060 shares in the last quarter. Wealthfront Advisers LLC bought a new stake in shares of Boston Scientific in the second quarter worth about $3,253,000. PensionDanmark Pensionsforsikringsaktieselskab increased its holdings in shares of Boston Scientific by 9.9% in the second quarter. PensionDanmark Pensionsforsikringsaktieselskab now owns 320,038 shares of the medical equipment provider's stock worth $13,659,000 after purchasing an additional 28,961 shares during the last quarter. Finally, Tocqueville Asset Management L.P. purchased a new stake in shares of Boston Scientific in the second quarter worth about $38,539,000. 89.07% of the stock is currently owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

A number of equities analysts recently commented on BSX shares. Deutsche Bank Aktiengesellschaft set a $48.00 price target on Boston Scientific and gave the company a "buy" rating in a research note on Thursday, October 29th. Robert W. Baird lifted their price objective on Boston Scientific from $50.00 to $51.00 and gave the stock an "outperform" rating in a research note on Thursday, October 29th. BTIG Research decreased their price objective on Boston Scientific from $56.00 to $49.00 and set a "buy" rating on the stock in a report on Thursday, October 29th. Weiss Ratings reiterated a "sell (d+)" rating on shares of Boston Scientific in a research report on Friday, October 2nd. Finally, Barclays lowered their target price on Boston Scientific from $48.00 to $45.00 and set an "equal weight" rating for the company in a research report on Friday, October 30th. One equities research analyst has rated the stock with a Strong Buy rating, twenty have given a Buy rating, eight have given a Hold rating and two have issued a Sell rating to the company's stock. According to MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and an average price target of $61.43.

Check Out Our Latest Stock Analysis on Boston Scientific

Boston Scientific News Roundup

Here are the key news stories impacting Boston Scientific this week:

  • Positive Sentiment: Boston Scientific reported that the SIMPLAAFY trial of its WATCHMAN FLX Pro heart device met its six-month primary endpoints. The results found two post-implant drug regimens non-inferior to dual-antiplatelet therapy, potentially supporting simpler treatment after the procedure. Article: SIMPLAAFY study results
  • Neutral Sentiment: Boston Scientific and Blackstone Life Sciences announced a $455 million collaboration to co-develop the VITALYST heart-pump technology. The arrangement may ease near-term development costs, but an analyst noted it could defer growth and leave longer-term uncertainty. Article: VITALYST collaboration Article: Analyst assessment of VITALYST deal
  • Negative Sentiment: A Zacks analysis flagged weakening earnings estimates, softer momentum in core businesses and major growth catalysts that may not arrive until 2028. Those concerns could overshadow the company’s valuation discount. Article: Valuation and earnings-growth analysis
  • Negative Sentiment: J.P. Morgan maintained a Hold rating, while TD Cowen also cut its rating to Hold; Barclays lowered its price target. The cautious analyst stance adds to concerns about near-term growth. Article: J.P. Morgan rating Article: TD Cowen rating Article: Barclays price-target change

Boston Scientific Stock Performance

Shares of NYSE:BSX opened at $43.58 on Wednesday. The company has a current ratio of 1.24, a quick ratio of 0.74 and a debt-to-equity ratio of 0.43. The firm's 50-day moving average is $44.55 and its 200 day moving average is $56.38. Boston Scientific Corporation has a 12 month low of $39.57 and a 12 month high of $105.65. The company has a market capitalization of $63.15 billion, a price-to-earnings ratio of 13.89, a PEG ratio of 1.29 and a beta of 0.60.

Boston Scientific (NYSE:BSX - Get Free Report) last issued its quarterly earnings results on Wednesday, October 28th. The medical equipment provider reported $0.73 earnings per share (EPS) for the quarter, hitting analysts' consensus estimates of $0.73. The firm had revenue of $5.14 billion during the quarter, compared to analyst estimates of $5.09 billion. Boston Scientific had a return on equity of 18.73% and a net margin of 16.62%. Boston Scientific's quarterly revenue was up 1.4% compared to the same quarter last year. During the same period last year, the company earned $0.75 EPS. Research analysts predict that Boston Scientific Corporation will post 3.17 EPS for the current year.

Boston Scientific Company Profile

(Free Report)

Boston Scientific Corporation is a medical technology company that develops, manufactures and markets devices used to diagnose and treat a broad range of complex medical conditions. Founded in 1979 and headquartered in Marlborough, Massachusetts, the company serves healthcare providers and patients worldwide.

Its products support minimally invasive procedures in areas including interventional cardiology, peripheral interventions, electrophysiology, endoscopy, urology and neuromodulation.

Featured Articles

Institutional Ownership by Quarter for Boston Scientific (NYSE:BSX)

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in Boston Scientific Right Now?

Before you consider Boston Scientific, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Boston Scientific wasn't on the list.

While Boston Scientific currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

The Infrastructure's Backbone: 10 Stocks Powering the AI Buildout Cover

The AI boom extends far beyond the biggest tech names. Discover 10 companies supplying the memory, storage, networking, semiconductor manufacturing, and power infrastructure that make AI possible. Learn where the next wave of AI investment opportunities may emerge—and the key risks investors should watch as the global AI buildout accelerates.

Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines